Advanced Non-Small-Cell Lung Cancer Patients with Low Tumor Mutation Burden Might Derive Benefit from Immune Checkpoint Inhibitors
Wei Nie,Mi-die Xu,Lu Gan,Yi Zhang,Kai Gu,Xue-Yan Zhang,Hui-Min Wang,Bo Yan,Jie Qian,Ping Gu,Bo Zhang,Shu-Yuan Wang,Fang Hu,Chang-Hui Li,Baohui Han
DOI: https://doi.org/10.2139/ssrn.3247897
2018-01-01
Abstract:Background: Results from previous studies showed an association between high tumor mutation burden (TMB) and more clinical benefit with immune checkpoint inhibitors in non-small cell lung cancer (NSCLC). However, patients with low TMB may also derive benefit from this treatment. This study aimed to investigate the association between TMB and survival in NSCLC patients received immune checkpoint inhibitors therapy.
What problem does this paper attempt to address?